As I see it: Search engine regulation

Share this article:

Until earlier this year, most drug manufacturers had been operating under the same policy relating to the use of sponsored links on search engines as had advertisers for other categories of products. That is, claims are made without disclosure on the search engine result page, driving consumers to a website where any required disclosures are made. The industry was shocked when FDA sent out 14 warning letters in a single day objecting to use of sponsored links without full compliance with FDA regulations. The letters effectively put an end to use of sponsored links for Rx products, at least for the time being, and also raised serious questions about online advertising generally. The industry is struggling to understand how FDA regulations and guidance documents affect various forms of online advertising. Guidance from FDA addressing the medium is long overdue.

FDA has already acknowledged the differences between media in promulgating regulations and issuing guidance documents. For example, FDA allows broadcast ads to contain a reference to the adequate provision of dissemination of approved package labeling instead of a full brief summary. It is time for FDA to do what FTC did long ago and acknowledge the idiosyncrasies of the internet.  

The FTC has issued documents dedicated to online advertising, acknowledging that the same rules apply but offering guidance as to how to comply. For example, FTC sets out with adequate specificity how to make “clear and conspicuous” disclosures online. FDA wouldn't need to start from scratch, but could simply adapt FTC guidance. Doing so would provide much needed clarity to the industry.

Tiffany Towers is a New York-based attorney in the advertising, marketing and promotions practice at Davis & Gilbert
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications